Skip to content
LexBuild

Importer of Controlled Substances; Notice of Registration; Mylan Technologies, Inc.

---
identifier: "/us/fr/2012-28485"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Importer of Controlled Substances; Notice of Registration; Mylan Technologies, Inc."
title_number: 0
title_name: "Federal Register"
section_number: "2012-28485"
section_name: "Importer of Controlled Substances; Notice of Registration; Mylan Technologies, Inc."
positive_law: false
currency: "2012-11-23"
last_updated: "2012-11-23"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Justice Department"
document_number: "2012-28485"
document_type: "notice"
publication_date: "2012-11-23"
agencies:
  - "Justice Department"
  - "Drug Enforcement Administration"
fr_citation: "77 FR 70187"
fr_volume: 77
---

#  Importer of Controlled Substances; Notice of Registration; Mylan Technologies, Inc.

By Notice dated March 8, 2012, and published in the *Federal Register* on March 20, 2012, 77 FR 16262, Mylan Technologies, Inc., 110 Lake Street, Saint Albans, Vermont 05478, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances:

| Drug | Schedule |
| --- | --- |
| Methylphenidate (1724) | II |
| Fentanyl (9801) | II |

The company plans to import the listed controlled substances in finished dosage form (FDF) from foreign sources for analytical testing and clinical trials in which the foreign FDF will be compared to the company's own domestically-manufactured FDF. This analysis is required to allow the company to export domestically-manufactured FDF to foreign markets.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Mylan Pharmaceuticals, Inc. to import the basic classes of controlled substances is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Mylan Pharmaceuticals, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named  company is granted registration as an importer of the basic classes of controlled substances listed.

Dated: November 14, 2012.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.